Exelixis, Inc. (EXEL) Stake Lowered by Nationwide Fund Advisors

Nationwide Fund Advisors cut its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 15.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 214,225 shares of the biotechnology company’s stock after selling 40,450 shares during the quarter. Nationwide Fund Advisors owned 0.07% of Exelixis worth $5,191,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. FMR LLC boosted its stake in shares of Exelixis by 2.0% in the second quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock worth $1,077,530,000 after acquiring an additional 857,452 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Exelixis by 7.2% in the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock worth $626,635,000 after acquiring an additional 1,706,893 shares during the last quarter. Matrix Capital Management Company LP boosted its stake in shares of Exelixis by 8.8% in the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock worth $372,343,000 after acquiring an additional 1,225,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Exelixis by 13.1% in the second quarter. Goldman Sachs Group Inc. now owns 7,059,232 shares of the biotechnology company’s stock worth $173,869,000 after acquiring an additional 818,782 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. boosted its stake in shares of Exelixis by 3.1% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 5,196,829 shares of the biotechnology company’s stock worth $127,997,000 after acquiring an additional 155,569 shares during the last quarter. Institutional investors and hedge funds own 81.19% of the company’s stock.

In other Exelixis news, EVP Jeffrey Hessekiel sold 27,302 shares of the business’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $24.28, for a total transaction of $662,892.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gisela Schwab sold 100,000 shares of the business’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $23.79, for a total value of $2,379,000.00. The disclosure for this sale can be found here. Insiders have sold 409,512 shares of company stock worth $10,836,442 in the last three months. 5.10% of the stock is currently owned by corporate insiders.

A number of brokerages have recently issued reports on EXEL. Needham & Company LLC lifted their price target on Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Oppenheimer reaffirmed a “hold” rating on shares of Exelixis in a research note on Monday, September 25th. Royal Bank of Canada lifted their price target on Exelixis from $33.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 17th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $26.00 price target on shares of Exelixis in a research note on Tuesday, October 17th. Finally, SunTrust Banks lifted their price target on Exelixis from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $31.38.

Exelixis, Inc. (NASDAQ:EXEL) opened at $26.58 on Thursday. The firm has a market capitalization of $7,816.44, a price-to-earnings ratio of 51.80, a price-to-earnings-growth ratio of 1.18 and a beta of 1.89. Exelixis, Inc. has a 12 month low of $14.22 and a 12 month high of $32.50.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.18. The company had revenue of $152.50 million for the quarter, compared to analyst estimates of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The firm’s revenue for the quarter was up 145.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) earnings per share. research analysts anticipate that Exelixis, Inc. will post 0.49 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://ledgergazette.com/2017/12/14/exelixis-inc-exel-stake-lowered-by-nationwide-fund-advisors.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply